Boehringer Ingelheim International GmbH v The Commissioner of Patents

Boehringer Ingelheim International GmbH (the applicant) sought to appeal a decision of the Commissioner of Patents (the respondent) refusing to grant a patent for a pharmaceutical substance. The dispute concerned the interpretation of the patentability requirements under the *Patents Act 1990* (Cth), specifically whether the applicant had adequately disclosed the invention and whether the invention was novel and involved an inventive step.

The primary legal issues before the High Court were whether the applicant had satisfied the requirements of section 40(3) of the *Patents Act 1990* (Cth) concerning the sufficiency of the patent disclosure, and whether the invention met the criteria for novelty and inventive step under sections 18(1)(a) and 18(1)(b) respectively. The court was required to consider the proper approach to assessing these patentability requirements in the context of pharmaceutical inventions.

The High Court held that the applicant had failed to satisfy the sufficiency requirement under section 40(3) because the patent specification did not adequately describe how to perform the invention. Specifically, the specification did not provide sufficient information to enable a skilled person to identify and isolate the claimed pharmaceutical substance without undue burden or experimentation. The court reiterated the principle that a patent must disclose the invention in a manner that is clear and complete enough for the invention to be performed by a person skilled in the art. The court found that the invention lacked novelty and an inventive step because the claimed substance was disclosed in prior art documents.

The appeal was dismissed.